Scynexis, Inc. (SCYX)

Trade SCYX now with
11/6/2020 8:53:34 AM SCYNEXIS Q3 Loss/Shr $0.28 Vs Loss $1.45 Last Year
8/10/2020 8:23:06 AM SCYNEXIS Q2 Net Loss $6.4 Mln Or $0.64/shr Vs Loss Of $8.4 Mln Or $1.58/shr Last Year
2/13/2020 8:09:49 AM SCYNEXIS Completes Patient Enrollment Ahead Of Schedule In 2nd Pivotal Phase 3 Study (VANISH-306) Of Oral Ibrexafungerp
1/8/2020 7:35:50 AM SCYNEXIS Announces Positive Results From The Second Interim Analysis Of Ongoing Phase 3 FURI Study
12/10/2019 6:24:22 AM SCYNEXIS Announces Pricing Of $35 Mln Public Offering Of Common Stock And Warrants
12/9/2019 4:06:06 PM SCYNEXIS Announces Launch Of Public Offering Of Common Stock And Warrants
11/12/2019 8:37:52 AM SCYNEXIS Q3 Net Loss $7.9 Mln Vs. Net Income $0.4 Mln Last Year
11/7/2019 8:13:16 AM SCYNEXIS Reports Results From First Phase 3 Registration Study Of Oral Ibrexafungerp In Vulvovaginal Candidiasis
9/18/2019 8:35:23 AM SCYNEXIS Completes Last-Patient In First Phase 3 Study Of Oral Ibrexafungerp For Treatment Of VVC
7/24/2019 9:02:27 AM SCYNEXIS Announces SPA Deal With FDA For Phase 3 Study Evaluating Oral Ibrexafungerp For Prevention Of Recurrent VVC
6/14/2019 8:32:20 AM SCYNEXIS Appoints Nkechi Azie As VP Of Clinical Development
5/30/2019 8:33:17 AM SCYNEXIS Completes Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration Of Ibrexafungerp
5/6/2019 8:32:36 AM SCYNEXIS Presents Data Further Supporting A Future NDA Submission Of Oral Ibrexafungerp For Vulvovaginal Candidiasis